podcasts Ratings /ratings/en/research-insights/podcasts/the-s-p-pharma-dose-episode-28-president-trump-s-american-patient-first-speech-placebo- content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

In This List

The S&P Pharma Dose - Episode 28: President Trump's American Patient First Speech - Placebo?

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

COMMENTS

ESG Concerns In Oil And Gas Sectors Led To A Surge In Downgrade Pressure In January, Which Was Realized By Mid-February

COMMENTS

As European Hotels Grapple With Prolonged Restrictions, Are Operators And Landlords Sharing The Pain?

COMMENTS

Pharma Outlook: Eighth Straight Year Of Credit Deterioration In 2021

Listen: The S&P Pharma Dose - Episode 28: President Trump's American Patient First Speech - Placebo?

The S&P Pharma Guy, Arthur Wong, shares S&P Global's initial thoughts on President Trump's recent speech on lowering drug prices. The speech questioned the validity of drug rebates and criticized foreign countries for paying too little for drugs, but stopped short of limiting proposing pharma list price increases or enabling Medicare to negotiate directly for pricing. Limited credit impact?

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back